FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096950003> ?p ?o ?g. }

• W3096950003 endingPage "175883592097004" @default.
• W3096950003 startingPage "175883592097004" @default.
• W3096950003 abstract "Background: Targeting immune checkpoints represents an immense breakthrough in cancer therapeutics. The prognostic value of hemoglobin (Hb) has been investigated in many malignancies including non-small cell lung cancer (NSCLC). However, the prognostic impact of pretreatment Hb count for immune checkpoint inhibitors (ICIs) in advanced NSCLC patients remains unclear. Methods: A total of 310 late-stage NSCLC patients who received ICI therapies between January 2015 and March 2019 were prospectively enrolled. We used a propensity score-matched cohort analysis for this study. Patients’ clinicopathological characteristics and pretreatment Hb concentration were assessed against the progression-free survival (PFS) and overall survival (OS) using the Kaplan–Meier method and Cox proportional hazards regression. Results: A propensity score (PS)-matched cohort analysis was applied to adjust for potential bias and to create two comparable groups according to patients’ clinicopathological characteristics. The patients with normal baseline Hb levels (⩾110 g/L) had significantly longer PFS [median: 10.0 versus 4.0 months, hazard ratio (HR): 0.63, 95% confidence interval (CI): 0.46−0.86; p = 0.001] and OS [median: 17.6 versus 10.5 months, HR (95% CI): 0.56 (0.40−0.79); p < 0.001] than those with decreased Hb count (<110 g/L) in a PS-matched cohort ( n = 255). For patients with normal pretreatment Hb levels, ICI combination therapy was significantly associated with better PFS [median: 11.1 versus 8.0 months, HR (95% CI): 0.74 (0.50−1.06); p = 0.09] and OS [median: 26.0 versus 12.9 months, HR (95% CI): 0.56 (0.37−0.86); p = 0.008] than monotherapy, but there was no such trend for patients with decreased baseline Hb levels. Conclusion: Our findings showed that normal pretreatment Hb count served as a favorable prognostic marker in advanced NSCLC patients treated with ICIs, representing an economical biomarker with readily measuring performance among all reported ones." @default.
• W3096950003 created "2020-11-09" @default.
• W3096950003 creator A5013973657 @default.
• W3096950003 creator A5017298596 @default.
• W3096950003 creator A5022121149 @default.
• W3096950003 creator A5022533710 @default.
• W3096950003 creator A5025466466 @default.
• W3096950003 creator A5028713452 @default.
• W3096950003 creator A5032154652 @default.
• W3096950003 creator A5042174429 @default.
• W3096950003 creator A5043791066 @default.
• W3096950003 creator A5053447705 @default.
• W3096950003 creator A5054209745 @default.
• W3096950003 creator A5056132441 @default.
• W3096950003 creator A5056791076 @default.
• W3096950003 creator A5060960928 @default.
• W3096950003 creator A5064745999 @default.
• W3096950003 creator A5071663299 @default.
• W3096950003 creator A5085880746 @default.
• W3096950003 creator A5089079624 @default.
• W3096950003 date "2020-01-01" @default.
• W3096950003 modified "2023-10-03" @default.
• W3096950003 title "Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer" @default.
• W3096950003 cites W1677755327 @default.
• W3096950003 cites W1866155365 @default.
• W3096950003 cites W1973794077 @default.
• W3096950003 cites W1982392243 @default.
• W3096950003 cites W1982488143 @default.
• W3096950003 cites W1988997650 @default.
• W3096950003 cites W2002253368 @default.
• W3096950003 cites W2019607817 @default.
• W3096950003 cites W2049014568 @default.
• W3096950003 cites W2057968408 @default.
• W3096950003 cites W2106787323 @default.
• W3096950003 cites W2108026891 @default.
• W3096950003 cites W2125257427 @default.
• W3096950003 cites W2134558329 @default.
• W3096950003 cites W2149837306 @default.
• W3096950003 cites W2155654588 @default.
• W3096950003 cites W2156353875 @default.
• W3096950003 cites W2198093519 @default.
• W3096950003 cites W2251438188 @default.
• W3096950003 cites W2260064945 @default.
• W3096950003 cites W2468576628 @default.
• W3096950003 cites W2478002927 @default.
• W3096950003 cites W2527905628 @default.
• W3096950003 cites W2560367415 @default.
• W3096950003 cites W2567564314 @default.
• W3096950003 cites W2570618306 @default.
• W3096950003 cites W2572174216 @default.
• W3096950003 cites W2580868502 @default.
• W3096950003 cites W2594592303 @default.
• W3096950003 cites W2635951006 @default.
• W3096950003 cites W2665058262 @default.
• W3096950003 cites W2802994639 @default.
• W3096950003 cites W2804408469 @default.
• W3096950003 cites W2886963239 @default.
• W3096950003 cites W2893602866 @default.
• W3096950003 cites W2893870376 @default.
• W3096950003 cites W2894103045 @default.
• W3096950003 cites W2897815318 @default.
• W3096950003 cites W2902220181 @default.
• W3096950003 cites W2903609600 @default.
• W3096950003 cites W2916508569 @default.
• W3096950003 cites W2930985014 @default.
• W3096950003 cites W2943699977 @default.
• W3096950003 cites W2951071083 @default.
• W3096950003 cites W2990769636 @default.
• W3096950003 cites W4232618296 @default.
• W3096950003 doi "https://doi.org/10.1177/1758835920970049" @default.
• W3096950003 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7649885" @default.
• W3096950003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33224276" @default.
• W3096950003 hasPublicationYear "2020" @default.
• W3096950003 type Work @default.
• W3096950003 sameAs 3096950003 @default.
• W3096950003 citedByCount "17" @default.
• W3096950003 countsByYear W30969500032021 @default.
• W3096950003 countsByYear W30969500032022 @default.
• W3096950003 countsByYear W30969500032023 @default.
• W3096950003 crossrefType "journal-article" @default.
• W3096950003 hasAuthorship W3096950003A5013973657 @default.
• W3096950003 hasAuthorship W3096950003A5017298596 @default.
• W3096950003 hasAuthorship W3096950003A5022121149 @default.
• W3096950003 hasAuthorship W3096950003A5022533710 @default.
• W3096950003 hasAuthorship W3096950003A5025466466 @default.
• W3096950003 hasAuthorship W3096950003A5028713452 @default.
• W3096950003 hasAuthorship W3096950003A5032154652 @default.
• W3096950003 hasAuthorship W3096950003A5042174429 @default.
• W3096950003 hasAuthorship W3096950003A5043791066 @default.
• W3096950003 hasAuthorship W3096950003A5053447705 @default.
• W3096950003 hasAuthorship W3096950003A5054209745 @default.
• W3096950003 hasAuthorship W3096950003A5056132441 @default.
• W3096950003 hasAuthorship W3096950003A5056791076 @default.
• W3096950003 hasAuthorship W3096950003A5060960928 @default.
• W3096950003 hasAuthorship W3096950003A5064745999 @default.
• W3096950003 hasAuthorship W3096950003A5071663299 @default.
• W3096950003 hasAuthorship W3096950003A5085880746 @default.
• W3096950003 hasAuthorship W3096950003A5089079624 @default.

• next